Dr. Rai on Novel Approaches in CLL

Kanti R. Rai, MD
Published: Monday, Feb 27, 2017



Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses some novel approaches being used in the field of chronic lymphocytic leukemia (CLL).

The newer developments in the field have been more targeted and therapeutical approaches so that, in the field of CLL, certain specific or molecular points have been identified, Rai explains. This includes BTK inhibition.

Additionally, these are unique to the leukemic cell and if researchers have a treatment specific to that target, then it is more likely that the cancer cell will be negatively affected or destroyed, he adds. Moreover, normal bone marrow cells will then be preserved.


Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses some novel approaches being used in the field of chronic lymphocytic leukemia (CLL).

The newer developments in the field have been more targeted and therapeutical approaches so that, in the field of CLL, certain specific or molecular points have been identified, Rai explains. This includes BTK inhibition.

Additionally, these are unique to the leukemic cell and if researchers have a treatment specific to that target, then it is more likely that the cancer cell will be negatively affected or destroyed, he adds. Moreover, normal bone marrow cells will then be preserved.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x